Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
about
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroABL tyrosine kinases: evolution of function, regulation, and specificityMED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signalingDigital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patientsFrom an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaChemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemiaSomatic mutations of the epidermal growth factor receptor and non-small-cell lung cancerThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPCombined surgical and molecular therapy: the gastrointestinal stromal tumor modelSequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potencyUbp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signalingAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainTwo different point mutations in ABL gene ATP-binding domain conferring primary imatinib resistance in a chronic myeloid leukemia (CML) patient: A case reportA screen to identify drug resistant variants to target-directed anti-cancer agentsCancer Evolution and the Limits of Predictability in Precision Cancer MedicineThe influence of subclonal resistance mutations on targeted cancer therapyCD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)Analysis of different HER-2 mutations in breast cancer progression and drug resistanceNew and emerging factors in tumorigenesis: an overviewTranslational implications of tumor heterogeneityKinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsRational approaches to improving selectivity in drug designMnk kinase pathway: Cellular functions and biological outcomesTargeting cancer with kinase inhibitorsTumour heterogeneity and the evolution of polyclonal drug resistanceMultidrug Resistance Proteins (MRPs) and Cancer TherapyClonal evolution in hematological malignancies and therapeutic implicationsResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitorsIn silico model-based inference: a contemporary approach for hypothesis testing in network biologyStructural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemiac-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutationsActivation of tyrosine kinases by mutation of the gatekeeper threonineTargeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinasesSmall Molecule Recognition of c-Src via the Imatinib-Binding ConformationThe structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase ConformationsStructural Bases for Stability–Function Tradeoffs in Antibiotic ResistanceTargeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitorsCrystal Structures of ABL-Related Gene (ABL2) in Complex with Imatinib, Tozasertib (VX-680), and a Type I Inhibitor of the Triazole Carbothioamide Class
P2860
Q21195212-E9A9F7C0-31F0-4485-89AD-D45D5127F39FQ24299738-34A5F146-7359-442A-AB8B-D76517B357BAQ24304423-A903C696-61D9-48EC-9EBB-2483A884E786Q24561669-E9F0017C-EDC3-4EFE-A13A-91670CDE3624Q24605527-47CA6933-3528-4284-8297-B043DFF9DCF1Q24622397-2EF1DD4A-0C06-4421-BEEE-F9E8E96A9D3FQ24648133-55B6E39B-7B26-4C9B-B0C3-723166FBF692Q24649549-B98F4275-C49A-4E23-ACB8-0829FE34975BQ24675987-16169C00-ADA8-4F67-B634-A5FF9C60121FQ24681743-1E582F52-32B4-43B0-96F0-15295A747D44Q24685070-F81A0728-CEA8-428E-83E7-2255A6503676Q24794765-A1FD87E6-0AE5-414E-A72E-3BEE5E58A000Q24800045-31AC2537-8829-4EC0-A13E-72895F543CF9Q24806543-9BCCA653-8E35-4C36-A576-F90B29BDDCC2Q26767415-D1228438-6271-48E4-8C32-0DFF23A68215Q26781693-3FE9C2BD-9DD7-4725-89F1-318EADD29881Q26783433-8C5F45E1-36E4-446F-93C8-53C061FE1A8EQ26797471-DF8CFA5F-E81D-4005-800B-B85484727F25Q26801253-B2F3E04B-1AEA-4C4F-99DA-08A8109B2AA7Q26822823-6C4AF3BD-E072-415F-966B-0E926FB78200Q26849792-02BC48F2-6A91-4DF1-ABF6-DC5C2DB91236Q26865357-F44174F4-007A-4A8C-B49D-F8B57DD863CBQ26865459-3A56ECCA-8F75-4EB2-98A6-D93DAC64C62AQ26865765-654B613A-AAC9-4B6D-966C-704BED8DE3ECQ26866803-84BD295E-70B1-41CB-B53F-3029F36B13E8Q26992204-ACB44CF6-7E67-4EC4-B501-7881560C5E9BQ27027655-444D6E42-68B5-4B47-A713-4D6AEFB8EF0CQ27028181-B75E8407-A533-4C15-95B3-45C9D96AF4F8Q27310990-460C0387-A3D1-432E-A394-FDE28790CBA7Q27339341-B43D0083-0078-4BCB-A7D8-3D6EA0436611Q27640723-7991CFE1-155D-41D7-B9B1-4564C672AE40Q27649203-BEB3C917-7A05-4C69-8A14-AF2ADEE42A77Q27652166-25827EA3-3A2F-49A5-84BD-E46C67269843Q27652488-DE7F598D-39AD-4748-9580-3D99C966AE7CQ27652602-39614732-E49E-4032-ACA8-97E9F5993E95Q27653890-A3F148AF-9901-46FC-91AE-E58DE5DF283AQ27654059-F2EB7984-EB33-4921-A687-D45845C31247Q27658160-4E83AC99-5F9C-45BC-ACEA-0C39B166C568Q27658951-B6BE8BB5-B58D-4766-8CF4-E965CF16854DQ27667290-8490C677-B15A-475F-BB09-E704EC32911E
P2860
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Multiple BCR-ABL kinase domain ...... risis chronic myeloid leukemia
@ast
Multiple BCR-ABL kinase domain ...... risis chronic myeloid leukemia
@en
type
label
Multiple BCR-ABL kinase domain ...... risis chronic myeloid leukemia
@ast
Multiple BCR-ABL kinase domain ...... risis chronic myeloid leukemia
@en
prefLabel
Multiple BCR-ABL kinase domain ...... risis chronic myeloid leukemia
@ast
Multiple BCR-ABL kinase domain ...... risis chronic myeloid leukemia
@en
P2093
P3181
P1433
P1476
Multiple BCR-ABL kinase domain ...... risis chronic myeloid leukemia
@en
P2093
Paquette RL
Sawyers CL
P304
P3181
P356
10.1016/S1535-6108(02)00096-X
P407
P577
2002-08-01T00:00:00Z